Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
Publishing timestamp: 2024-02-10 08:00:01
Summary
The demand for weight loss drugs is surpassing the supply, causing shortages and difficulties for patients to access injectable treatments. Novo Nordisk and Eli Lilly, the dominant weight loss drugmakers, are making progress in increasing supply and have provided positive updates to investors. The popularity of these drugs is expected to continue to rise, and both companies are working to meet the demand. Other companies are also entering the market, but Novo Nordisk and Eli Lilly aim to maintain their edge. They have invested in expanding production capacity and are pursuing acquisitions to boost supply. Alternative forms of weight loss drugs, such as oral medications, may also help alleviate supply constraints in the future.
Sentiment: NEUTRAL
Tickers: LLY, AMGN, AZN, AZN-GB, CTLT, PFE, ROG-CH, NOVO.B-DK, NVO,
Keywords: eli lilly and co, catalent inc, astrazeneca plc, novo nordisk a/s, biotechnology, business, pfizer inc, breaking news, weight management, biotech and pharmaceuticals, pharmaceuticals, health care industry, business news, roche holding ag, amgen inc,